Antibiotic Exclusivity: Which Vision Will GAIN Upper Hand In FDA List-making?
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry presenters tell FDA a broad list of potential diseases will attract more developer interest, but advocacy groups push for more targeted criteria during a public hearing on the new exclusivity incentive.